Related Experiment Video

Updated: Jun 27, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

[Role of myostatin in wasting syndrome associated with chronic diseases]

Elisabet Zamora1, Amparo Galán, Rafael Simó

  • 1Servicio de Cardiología. Departamento de Medicina. Universitat Autònoma de Barcelona. Hospital Universitari Germans Trias i Pujol. Badalona. Barcelona. España. e.zamora@telefonica.net

Medicina Clinica
|December 17, 2008
PubMed

Insights

Muscle wasting, or sarcopenia, is linked to poor disease outcomes. Myostatin protein is a key factor, and substances that counteract it may offer new therapeutic strategies for muscle wasting.

Area of Science:

  • Biochemistry
  • Physiology
  • Molecular Biology

Context:

  • Muscle wasting, a prevalent complication in chronic diseases, significantly worsens patient prognosis.
  • Sarcopenia, the age-related loss of muscle mass and strength, is a critical health concern.
  • The precise mechanisms driving sarcopenia remain incompletely understood, highlighting the need for further research.

Purpose:

  • To explore the physiological role of myostatin, a protein in the transforming growth factor beta superfamily.
  • To investigate the potential of myostatin-inhibiting substances as therapeutic agents for muscle wasting conditions.

Summary:

  • Myostatin, identified through studies on myostatin-deficient mice exhibiting muscle hypertrophy, plays a crucial role in regulating muscle mass.
  • Research indicates that myostatin is implicated in the pathophysiology of sarcopenia and other muscle wasting syndromes.
  • Emerging substances designed to inhibit myostatin offer promising avenues for treatment, targeting various underlying pathological mechanisms.

Impact:

  • Advances in understanding myostatin's function can lead to novel therapeutic strategies for combating muscle wasting.
  • Developing effective treatments for sarcopenia could significantly improve the quality of life and outcomes for patients with chronic diseases.
  • Further research is essential to fully elucidate the complex processes of muscle wasting and to develop effective preventative and therapeutic interventions.

More Related Videos

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice04:01

A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice

Published on: June 14, 2024

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.